The BioNTech founders who basically saved the world with mRNA just said “thanks for the memories” and are pedaling off to start their own playground.
Ugur Sahin and Özlem Türeci, the married scientist duo behind the Covid vaccine that turned BioNTech into a household name (and a temporary Wall Street darling), announced Tuesday they will step down from their CEO and CMO roles by the end of 2026 to launch a fresh biotech startup laser-focused on next-generation mRNA innovations.
Investors responded with the enthusiasm of someone who just discovered their lottery ticket was for next week’s draw: BioNTech’s American depositary receipts tanked as much as 21% in pre-market trading.
One major shareholder called the departure “devastating” for a company at a “critical juncture,” which is polite finance-speak for “we’re all going to need therapy now.”
The couple, who prefer lab coats to boardroom suits, apparently feel the giant they built has grown up and needs grown-up managers who actually enjoy spreadsheets and commercialization timelines.
Sahin himself put it bluntly: the company is shifting from dreamy academic research to the gritty world of speed, execution, and industrialization—tasks better suited to people who don’t arrive at work on a mountain bike looking like they just escaped a physics lecture.
BioNTech, once a plucky Mainz startup with an academic soul, ballooned to a $26 billion market cap after the pandemic windfall.
That’s still seven times its 2019 debut level, but a far cry from peak-Covid glory when everyone pretended to understand lipid nanoparticles.
Now the founders are handing over the keys and taking some mRNA tech rights with them (BioNTech gets a minority stake in the new venture, because even visionaries like a little equity upside).
The move leaves shareholders wondering if the magic was in the people or the platform—while the couple heads back to pure innovation, probably on matching mountain bikes.
Leave a Reply